S
Serina Therapeutics, Inc. (SER)
ASE – Real vaqt narxi. Valyuta: USD
1.63
+0.03 (1.88%)
Yopilishda: May 12, 2026, 3:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
ASE – Real vaqt narxi. Valyuta: USD
1.63
+0.03 (1.88%)
Yopilishda: May 12, 2026, 3:59 PM EDT
Serina Therapeutics, Inc., biotexnologiya kompaniyasi, nevrologik kasalliklar va og'riqlarni davolash uchun dori vositalarini ishlab chiqadi. Uning yetakchi mahsulot nomzodi SER 252 (POZ-apomorfin), ilg'or Parkinson kasalligini davolash uchun POZ kon'yugati bo'lib, 1-faza klinik sinovlarida; va POZ-lipidlar, lipid nanozarralaridagi PEG-lipidlar uchun immunogen bo'lmagan muqobil variantdir. Kompaniya, shuningdek, 1a-faza klinik sinovlarini yakunlagan, Parkinson kasalligining dastlabki bosqichlari va uyqusiz oyoq sindromini davolash uchun rotigotinning POZ kon'yugati bo'lgan SER 214ni ishlab chiqmoqda. Bundan tashqari, u yuqumli kasalliklar uchun lipid nanozarralar orqali yetkaziladigan ribonuklein kislotali vaktsinalarda POZ texnologiyasini ishlab chiqadi. Serina Therapeutics, Inc. 2006-yilda tashkil etilgan va shtab-kvartirasi Xantsvill, Alabama shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Balkrishan Gill Ph.D. | Executive Co-Chairman of the Board |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board |
| Dr. Joshua Thomas Ph.D. | Head of Chemistry |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Srini Tenjarla Ph.D. | Chief Technical Operations Officer |
| Mr. Gregory S. Curhan | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | DEFA14A | a2026proxydefa14a.htm |
| 2026-04-27 | DEF 14A | ser-20260427.htm |
| 2026-04-21 | 8-K | ser-20260415.htm |
| 2026-04-17 | PRE 14A | ser-20260417.htm |
| 2026-03-27 | 10-K/A | ser-20251231.htm |
| 2026-03-25 | S-8 | forms-8.htm |
| 2026-03-23 | 8-K | ser-20260317.htm |
| 2026-01-30 | S-3 | forms-3.htm |
| 2026-01-28 | 8-K | ser-20260127.htm |
| 2026-01-15 | 8-K | ser-20260109.htm |
| Mr. Steven A. Ledger | CEO & Director |